Hematological Malignancies | Norton Healthcare

Indication: Hematological Malignancies

A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies

Advanced Solid Tumors and Heme Malignancies

Sub-indication: DLBCL and MCL

Line of Therapy: 2nd or 3rd line

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Prelude Therapeutics

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.